Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Taysha Gene Therapies Inc
TSHA | US
6.43
USD0.48
8.07%
TSHA | US
About Taysha Gene Therapies Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
6.43
Open
6.10
High
6.50
Low
5.93
Taysha Gene Therapies Inc. a gene therapy company focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas Texas.
View LessTSHA | US
Risk
122.8
Sharpe
4.10
Luna's Score
55/100
Recommendation
Hold
Luna says (TSHA | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
143.6%1 month
122.8%3 months
83.1%6 months
79.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.82
Debt to equity
0.53
Debt to assets
0.29
Ent. to EBITDA
-0.61
Ent. to rev.
23.38
PEG
-
Other Fundamentals
EBITDA
-75.72M
MarketCap
1.32B
MarketCap(USD)
1.32B
Div. yield
-
Op. margin
-1.92K
Erngs. growth
-
Rev. growth
-53.60
Ret. on equity
-318.69
Short ratio
11.29
Short perc.
13.29
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.17
Range1M
2.47
Range3M
2.47
Volumes: Market Activity
Rel. volume
1.91
Price X volume
39.08M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.61 | - | Cheaper |
| Ent. to Revenue | 23.38 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.82 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 83.06 | - | Par |
| Debt to Equity | 0.53 | -1.23 | Expensive |
| Debt to Assets | 0.29 | 0.25 | Par |
| Market Cap | 1.32B | - | Emerging |
